Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.955
+0.055 (2.89%)
Aug 5, 2026, 10:25 AM EDT - Market open

Allogene Therapeutics Stock Forecast

Stock Price Forecast

According to 12 analysts polled by S&P Global, Allogene Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $9.00. The average 1-year stock price forecast is 360.36% higher than the current stock price, while the lowest is $4.00 (+104.60%) and the highest is $14 (+616.11%).

Price Target: $9.00 (+360.36%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$4.00$9.00$9.00$14
Change+104.60%+360.36%+360.36%+616.11%
* Price targets were last updated on May 29, 2026.

Analyst Ratings

The average analyst rating for Allogene Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingFeb '26Mar '26Apr '26May '26Jun '26Jul '26
Strong Buy101010988
Buy333333
Hold112221
Sell110000
Strong Sell000000
Total151515141312

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
William Blair
William Blair
Buy
Maintains
n/a
BuyMaintainsn/an/aAug 5, 2026
Piper Sandler
Piper Sandler
Buy
Maintains
$10
BuyMaintains$10+411.51%May 29, 2026
Oppenheimer
Oppenheimer
Buy
Reiterates
$7
BuyReiterates$7+258.06%May 14, 2026
RBC Capital
RBC Capital
Buy
Maintains
$9
BuyMaintains$9+360.36%May 14, 2026
Canaccord Genuity
Canaccord Genuity
Buy
Maintains
$14
BuyMaintains$14+616.11%May 14, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
6.67K
Revenue Next Year
14.59M
from 6.67K
Increased by 218,711.84%
EPS This Year
-0.61
from -0.85
EPS Next Year
-0.68
from -0.61
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
114.09M156.00K95.00K22.00K-6.67K
Operating Income
-180.19M-335.54M-314.49M-257.48M-206.93M-214.74M
Net Income
-182.05M-340.41M-327.27M-257.59M-190.89M-197.35M
EPS
-----0.85-0.61
Free Cash Flow
-85.97M-111.74M-134.26M-99.13M-80.73M-156.00M
No. Analysts
-----9
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High60,000
Avg6,670
Lown/a

Revenue Growth

Revenue Growth20272028
High
951,924.0%
Avg
218,711.8%
Low
-100.0%

EPS Forecast

EPS202620272028
High-0.58
Avg-0.61
Low-0.66

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-